Age and Genetics Influence Real-World CLL Treatment Decisions

Age and genetics are the primary drivers of front-line treatment decisions for chronic lymphocytic leukemia (CLL) in real-world clinical practice, according to a French multicenter study presented at the European Hematology Association (EHA) 2025 Congress in Milan, Italy.

The study, which analyzed data from 282 patients with CLL across France, identified two distinct treatment profiles shaped not by clinical trial data alone, but by patient-specific factors including age, genetic prognostic markers and logistical considerations. Researchers found that physicians most frequently cited genetic factors — such as TP53 abnormalities and IGHV mutational status — as the top influence when selecting initial therapy, followed by fixed treatment duration and patient logistics like travel burden or caregiver availability.

These findings highlight a growing shift toward personalized, risk-adapted approaches in CLL care, where biological markers and individual patient circumstances weigh more heavily than standardized protocols. While clinical trials often emphasize progression-free survival or overall response rates, real-world decisions appear to balance efficacy with quality of life, treatment burden, and long-term tolerability — particularly in older or comorbid patients.

Among the genetic factors evaluated, TP53 disruption emerged as a critical determinant, frequently steering clinicians toward fixed-duration regimens such as venetoclax-based combinations, which offer time-limited therapy with deep remission potential. In contrast, patients with favorable genetics — like mutated IGHV without high-risk lesions — were more likely to receive continuous therapies, such as BTK inhibitors, especially when age and comorbidities permitted prolonged treatment.

Age played a dual role: older patients were more often prescribed fixed-duration approaches to minimize cumulative toxicity and treatment duration, while younger, fitter patients were considered candidates for continuous therapies aimed at sustained disease control. However, chronological age alone did not dictate decisions; physicians integrated biological age, frailty indices, and patient preferences into their assessments.

Logistical factors — including distance to treatment centers, need for frequent monitoring, and availability of home support — significantly influenced regimen selection, particularly for therapies requiring intensive intravenous schedules or frequent clinic visits. These practical considerations sometimes led to deviations from guideline-recommended regimens, underscoring the gap between ideal trial populations and real-world diversity.

The study’s authors emphasized that treatment choices in CLL are increasingly multidimensional, requiring oncologists to weigh molecular risk, patient fitness, lifestyle, and treatment goals in tandem. They noted that while guidelines provide a framework, real-world oncology demands flexibility to accommodate individual variability — especially in a disease as heterogeneous as CLL, where outcomes can vary widely based on subtle genetic differences.

These insights align with broader trends in oncology toward precision medicine and shared decision-making, where patients are actively involved in weighing trade-offs between treatment intensity, duration, side effects, and lifestyle impact. As novel agents continue to expand the therapeutic landscape, understanding how real-world factors shape uptake will be essential for optimizing care delivery and ensuring equitable access to effective therapies.